- Home
- GO vs KURA Comparison
GO vs KURA Comparison
Compare GO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GO | KURA |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GO | KURA |
|---|---|---|
| Price | $12.65 | $13.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $11.30 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 2.8M | 2.2M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | $67,482,000.00 |
| Revenue This Year | $2.48 | $28.28 |
| Revenue Next Year | $3.91 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.26 | ★ 25.24 |
| 52 Week Low | $5.66 | $7.36 |
| 52 Week High | $18.22 | $13.90 |
Technical Indicators
Market Signals| Indicator | GO | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 64.67 |
| Support Level | $8.92 | $7.96 |
| Resistance Level | N/A | $13.90 |
| Average True Range (ATR) | 0.49 | 0.68 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 93.95 | 73.57 |
Price Performance
Historical ComparisonAbout GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.